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Abstract
Background: Hirschsprung's	disease	(HSCR)	is	a	congenital	gastrointestinal	disorder,	
characterized by enteric ganglia absence in part or entire of the colon, due to abnor-
mal	colonization	and	migration	of	enteric	neural	crest	cells	(ENCCs)	during	develop-
ment.	Currently,	besides	surgery	which	is	the	main	therapy	for	HSCR,	the	potential	of	
stem	cell-based	transplantation	was	investigated	as	an	alternative	option.	Although	
promising, it has limitations, including poor survival, differentiation, and migration 
of	the	grafted	cells.	We	hypothesized	that	modulation	of	extracellular	factors	dur-
ing	 transplantation	 could	 promote	 ENCCs	 proliferation	 and	 migration,	 leading	 to	
increased	 transplantation	efficiency.	Considering	 that	 the	RhoA/ROCK	pathway	 is	
highly	involved	in	cytoskeletal	dynamics	and	neurite	growth,	our	study	explored	the	
effect	of	inhibition	of	this	pathway	to	improve	the	success	of	ENCCs	transplantation.
Methods: Enteric	neural	crest	cells	were	isolated	from	rat	embryos	and	labeled	with	
a	GFP-tag.	Cell	viability,	apoptosis,	differentiation,	and	migration	assays	were	per-
formed	with	and	without	RhoA/ROCK	inhibition.	Labeled	ENCCs	were	transplanted	
into the muscle layer of an induced hypoganglionic rat model followed by intraperito-
neal	injections	of	ROCK	inhibitor.	The	transplanted	segments	were	collected	3	weeks	
after for histological analysis.
Key Results: Our	results	showed	that	inhibition	of	ROCK	increased	viable	cell	num-
ber,	differentiation,	and	migration	of	ENCCs	 in	vitro.	Moreover,	 transplantation	of	
labeled	 ENCCs	 into	 the	 hypoganglionic	 model	 showed	 enhanced	 distribution	 of	
grafted	ENCCs,	upon	treatment	with	ROCK	inhibitor.
Conclusions and Inferences: ROCK	inhibitors	influence	ENCCs	growth	and	migration	
in	vitro	and	 in	vivo,	and	should	be	considered	to	 improve	the	efficiency	of	ENCCs	
transplantation.
K E Y W O R D S
ENCCs,	enteric	nervous	system,	hirschsprung's	disease,	RhoA/ROCK	pathway,	
transplantation
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1  | INTRODUC TION
Hirschsprung's	disease	(HSCR)	is	a	congenital	gut	motility	disorder,	
characterized by the absence of enteric ganglia along different in-
testinal lengths. It results from the failure of enteric neural crest 
cells	(ENCCs)	to	colonize	the	gut	during	fetal	development.1	Genetic	
studies have identified rare coding and non-coding variants in sev-
eral	genes	as	the	leading	cause	of	HSCR,	but	they	only	explain	~30%	
of the cases.2	HSCR	has	 an	 incidence	of	1:5000	 live	births	 and	 is	
characterized by constipation, abdominal distension, and megaco-
lon.	At	present,	surgical	removal	of	the	aganglionic	segment	 is	the	
main	treatment	for	HSCR.3	However,	in	some	cases,	surgery	cannot	
relieve all symptoms and can lead to secondary complications, such 
as enterocolitis. Therefore, there is a need for novel treatment op-
tions	for	HSCR.
Over the last 10-15 years, stem cell-based therapy to replace 
the	missing	enteric	nervous	system	(ENS)	in	HSCR	has	been	investi-
gated.	Transplanting	ENCCs	into	the	aganglionic	bowel	could	lead	to	
an improvement of gut motility in animal models.4-7	However,	ENCC	
transplantation has limitations, namely poor survival, differentiation, 
and migration of the grafted cells.8 It was speculated that these lim-
itations could be attributed to the overall condition of the grafted 
cells on the one hand and the condition of the environment in which 
cells were transplanted on the other hand. In the latter, collagen 
overabundance,9,10 inflammation cascade,11 and growth cytokine 
deficiency seem to play a role. Therefore, it is reasonable to assume 
that	 the	modulation	of	extracellular	 factors	during	 transplantation	
could promote engraftment and ultimately lead to an increase in the 
transplantation efficiency.
The	 RhoA/ROCK	 pathway	 consists	 of	 RhoA	 and	 downstream	
target	 homologous	 isomers,	 ROCK1,	 and	 ROCK2.12 Regulation of 
this pathway is essential for cytoskeletal dynamics and cell motility.13 
ROCK	activation	can	inhibit	axonal	growth	and	neural	regeneration	
in the central nervous system.14,15 Based on these findings, inhibi-
tion	of	the	RhoA/ROCK	pathway	is	considered	a	rational	treatment	
approach for neurological disorders, with several studies demon-
strating	 remarkable	 recovery	effects	using	 inhibitors	 like	Y-27632,	
Fasudil,	and	BA-210.16,17	Moreover,	 the	migration	and	axon	exten-
sion of enteric neurons was found increased upon inhibition of the 
ROCK	pathway	by	Y-27632	exposure,18	possibly	by	permitting	RAC1	
activation.19	Apart	from	the	nervous	system,	the	ROCK	pathway	is	
also involved in the regulation of intestinal smooth muscles contrac-
tion.20	Hyper-activation	of	Rho-kinase	has	also	been	reported	in	the	
aganglionic segment of endothelin-B receptor gene-deficient rats 
(Ednrb−/−),	a	known	HSCR	model.21 Therefore, the precise function 
of	the	RhoA/ROCK	pathway	on	the	ENS	requires	further	research,	
but	it	seems	reasonable	that	inhibition	of	the	RhoA/ROCK	pathway	
could	be	one	of	the	factors	that	positively	affects	the	ENCCs	based	
therapy after transplantation.
In	this	study,	we	investigated	the	role	of	the	RhoA/ROCK	path-
way	in	both	ENCC	culture	and	transplantation	into	the	hypogangli-
onic	segments	of	rat	models.	We	hypothesized	that	inhibition	of	this	
pathway could improve transplantation efficiency by promoting the 
growth,	differentiation,	and	migration	of	ENCCs,	thereby	leading	to	
a more successful transplantation outcome.
2  | MATERIAL S AND METHODS
2.1 | Animal preparation
One	 hundred	 adult	 Sprague-Dawley	 (SD)	 rats	 (both	 sexes)	 with	 a	
bodyweight of 200 ± 50 g and twenty SD pregnant female rats were 
obtained	 from	 the	 Experimental	 Animal	 Center	 of	 Xi'an	 Jiaotong	
University,	Health	Science	Center.	They	were	used	to	establish	the	
hypoganglionic	model	(see	2.8)	or	to	isolate	the	ENCCs	primary	cul-
tures	 (see	2.2),	 respectively.	All	 rats	were	 socially	housed	and	 fed	
with standard diet and water. The bodyweight was measured every 
other	day.	All	animals	were	handled	 in	accordance	with	the	guide-
lines	 provided	 by	 the	 ethics	 committee	 and	 the	 National	 Health	
Institute	regarding	the	care	and	use	of	 laboratory	animals.	The	ex-
periment	additionally	adhered	to	ARRIVE	guideline	standards.
2.2 | ENCCs culture
Pregnant	 SD	 rats	 carrying	 14-day-old	 embryos	 were	 sacrificed	
by	 administering	 an	 overdose	 of	 anesthesia	 (7%	 chloral	 hydrate).	
Embryos	were	 delivered	 via	 cesarean	 section.	 The	 intestinal	 tract	
of	 each	 embryo	was	 isolated	 and	 put	 on	 ice.	Mesentery	 and	 ves-
sels were carefully removed under a stereomicroscope. The intes-
tines	were	cut	into	pieces	of	1	mm	and	dissociated	with	0.25%	w/v	
collagenase	IV	(Gibco,	17104019)	and	0.25%	w/v	dispase	II	(Sigma,	
42613-33-2),	for	40	minutes,	at	37°C.	During	incubation,	the	sample	
was	vortexed	every	5	minutes.	Subsequently,	the	cell	suspension	was	
Key points
•	 Enteric	 neural	 crest	 cells	 (ENCCs)	 based	 therapy	 for	
Hirschsprung's	disease	 (HSCR)	has	obtained	promising	
progress, but there are major limitations including poor 
survival, differentiation, and migration ability of trans-
planted	ENCCs.
•	 Modulation	of	environmental	 factors	during	transplan-
tation could promote transplantation efficiency, func-
tioning as a potential optimizing target.
• Results in the present work suggest that inhibition of the 
ROCK	 pathway	 improved	 the	 growth,	 differentiation,	
and	migration	of	ENCCs	in	vitro,	and	enhanced	distribu-
tion	of	grafted	ENCCs	after	transplantation	in	vivo.
•	 This	 study	 highlights	 the	 impact	 of	 the	 RhoA/ROCK	
pathway on enteric neural cells and emphasizes 
the	 importance	 of	 the	 extracellular	 environment	 in	
Hirschsprung's	disease.
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filtered through a 100 µm mesh filter and centrifuged at 800 rpm 
for	 4	minutes.	 Cells	were	 resuspended	 and	 plated	 at	 a	 density	 of	
2 × 105	cells/mL	in	complete	culture	medium,	which	was	DMEM	F12	
(1:1)	 (Hyclone,	 SH30023.01),	 supplemented	with	1.0%	N2	 supple-
ment	(Gibco,	A1370701),	1.0%	B-27	supplement	(Gibco,	12587010),	
5	ng/mL	recombinant	basic	fibroblast	growth	factor	(bFGF)	(Gibco,	
PHG0021),	 5	 ng/mL	 recombinant	 epidermal	 growth	 factor	 (EGF)	
(Gibco,	PHG0311),	2	mmol/L	L-glutamine,	and	100	U/mL	penicillin-
streptomycin	(Gibco,	15140148).	Cells	were	cultured	at	37°C,	in	5%	
CO2,	for	7	days	to	form	neurospheres.
To	split	the	ENCCs,	neurospheres	were	harvested	by	centrifuga-
tion	and	dissociated	into	smaller	neurospheres	using	0.25%	w/v	col-
lagenase	IV	and	dispase	II,	at	37°C	for	5	minutes.	Cell	clusters	were	
re-cultured	in	complete	culture	medium.	To	identify	ENCCs	markers,	
neurospheres	were	harvested,	fixed,	and	dropped	on	coverslips	for	
immunofluorescence	staining	(see	2.10).
2.3 | Viable cell counting assay
Single	 ENCCs	 obtained	 by	 trypsinization	 of	 neurospheres	 were	
seeded	at	 a	density	of	4000	cells/well	 in	96-well	 plates	 in	 com-
plete	 culture	 medium	 (see	 2.2).	 Forty-eight	 hours	 later,	 cells	
were	 treated	 with	 different	 RhoA/ROCK	 inhibitors:	 CCG-1423	
(APExBIO,	 B4897),	 Y-27632	 dihydrochloride	 (APExBIO,	 A3008),	
SR-3677	 (APExBIO,	B1294),	 or	with	PBS.	 For	 each	 inhibitor,	 the	
following	concentrations	were	used:	0.01,	0.1,	1,	10,	100	µmol/L.	
After	72	hours	of	 treatment,	cells	 in	24-well	plates	were	 imaged	
and	counted.	Cells	in	96-well	plates	were	used	to	assess	cell	viabil-
ity	using	the	Cell	Counting	Kit-8	(7-Sea	Biotech,	C008-3),	accord-
ing	to	the	manufacturer's	instructions.	In	brief,	the	CCK-8	kit	uses	
WST-8	 tetrazolium	 sodium	 salt,	which	 produces	 a	water-soluble	
formazan dye upon bio-reduction by cellular dehydrogenases. 
The amount of formazan produced is directly proportional to the 
number	of	living	cells;	therefore,	the	absorbance	(OD	optical	den-
sity)	at	450	nm	indicates	viable	cell	numbers,	which	was	measured	
4	hours	later	after	addition	of	WST-8.
2.4 | Differentiation of ENCCs under treatment 
with inhibitors
Single	 ENCCs	 obtained	 by	 trypsinization	 of	 neurospheres	 were	
seeded	 at	 a	 density	 of	 4	 ×	 105	 cells/well	 in	 6-well	 plates,	 and	
1 × 105	cells/well	on	coverslips	in	24-well	plates,	in	the	complete	
culture	medium	(see	2.2).	After	48	hours,	2%	fetal	calf	serum	(FCS)	
(Gibco,	A3161001C)	was	 added	 to	 each	well	 to	 induce	 differen-
tiation. Thereafter, cells were treated with different inhibitors: 
10	 µmol/L	 CCG-1423,	 10	 µmol/L	 Y-27632	 dihydrochloride,	 and	
1	µmol/L	SR-3677	 for	72	hours.	PBS	was	used	as	 control.	After	
treatment,	cells	in	the	6-well	plates	were	lysed	for	Western	blot-
ting,	 and	 cells	 on	 coverslips	were	 fixed	 and	 immunostained	 (see	
2.10).
2.5 | Trans-well migration assays
ENCC	migration	was	 assessed	using	Millicell	Hanging	Cell	Culture	
Inserts	 (Millipore)	 in	 24-well	 plates.	 A	 total	 of	 200	 µL	 of	 single	
ENCC	suspension	 trypsinized	 from	neurospheres	were	plated	at	 a	
density of 5 × 104	cells/mL	in	complete	culture	medium	(see	2.2)	in	
the	 top	chamber.	 In	addition,	600	µL	of	complete	culture	medium	
supplemented	with	 2.0%	 FCS	was	 added	 to	 the	 bottom	 chamber	
for	 chemo-attraction.	 Thereafter,	 either	 10	 µmol/L	 CCG-1423,	
10	 µmol/L	 Y-27632,	 1	 µmol/L	 SR-3677,	 or	 PBS	 (used	 as	 control)	
were	added	to	both	the	top	and	bottom	chambers.	After	72	hours	
of	incubation,	cells	were	fixed	on	the	membrane	with	methanol	and	
stained with gentian violet. The number of cells that passed through 
the membrane was counted to assess migration.
2.6 | Cell apoptosis assay
Single	ENCCs	trypsinized	from	neurospheres	were	plated	in	6-well	
plates	at	4	×	105	cells/well	 in	complete	medium	(see2.2).	48	hours	
later,	 cells	were	 treated	with	 10	µmol/L	 of	CCG-1423,	 10	µmol/L	
of	Y-27632,	1	µmol/L	of	SR-3677,	or	PBS.	After	72	hours	of	treat-
ment, cells were collected and apoptosis was determined using the 
Annexin	V:	PE	Apoptosis	Detection	Kit	I	(BD,	559763)	according	to	
the	manufacturer's	instructions.
2.7 | ENCC labeling with a fluorescent tag
Lentivirus	 vector	 HBLV-GFP-PURO	 was	 obtained	 from	 HANBIO	
(Han	 Biotech,	 04021724,	 Shanghai).	 Transduction	 was	 performed	
according	to	the	manufacturer's	protocol.	In	brief,	small	ENCC	colo-
nies	obtained	from	gentle	dissociation	were	seeded	in	6-well	plates	
at	a	density	of	4	×	105 cells/well. Transduction was performed on 
day	two	with	different	multiplicity	of	infection	(MOI):	5×,	25×,	125×,	
or	250×	lentivirus,	along	with	6	µg/mL	polybrene	(Han	Biotech,	HB-
PB-500).	Plates	were	centrifuged	at	37°C,	500	×	g for 30 minutes, 
and then returned to the incubator. The medium was changed on day 
4,	and	the	cells	were	analyzed	on	day	6	via	fluorescent	imaging	and	
FACS.	The	FACS	gating	strategy	was	delimited	to	distinguish	GFP+ 
cells according to negative control population.
2.8 | Establishment of the rat hypoganglionic model
All	surgical	procedures	used	in	this	study	had	been	previously	de-
scribed.22 In summary, the procedure is as follows. Preoperative 
fasting was performed for 8 hours. Rats were operated with a mid-
line	incision	under	anesthesia	(7%	chloral	hydrate).	A	soft	tube,	with	
a diameter of 2 mm, was inserted into the anus as an indicator of 
the length. The descending colon segment located 5 cm away from 
anus, was wrapped in 1-cm-wide filter paper soaked thoroughly 
with	0.1%	benzalkonium	chloride	 (BAC,	Tokyo	Chemical	 Industry,	
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63449-41-2),	 and	 remained	 wrapped	 for	 30	 minutes.	 A	 medical	
gauze was used to isolate the treated colon from the abdominal cav-
ity.	After	removing	the	filter	paper,	the	target	segment	was	washed	
three times thoroughly with saline and returned to its original posi-
tion.	Histological	evaluation	of	treated	segments	was	performed	at	
2,	4,	and	6	weeks	after	surgery,	by	immunohistochemistry	of	beta-
III-tubulin	(Tuj1)	and	protein	gene	product	9.5	(PGP9.5),	in	order	to	
determine	ENS	status.
2.9 | ENCCs transplantation
Three weeks after establishment of the hypoganglionic model, 
transplantation was performed under the same fasting and anes-
thesia conditions. Three different groups having 20 rats each were 
divided	as	 follows:	ENCC-only	group,	ENCC	+	Y-27632	group,	and	
the control group. For the first two groups, 5 × 106	cells/mL	GFP-
labeled	ENCCs	were	transplanted	into	the	hypoganglionic	segments	
by	microinjection	 of	 20	µL	 cell	 suspension	 for	 each	 injection	 into	
the	muscle	layers	at	the	central	surface	at	0.3.6.9	clockwise	position	
(see	Figure	6B).	The	control	group	was	injected	with	PBS	under	the	
same conditions.
Continued	 treatment	 with	 the	 inhibitor	 started	 1	 day	 after	
surgery	 by	 intraperitoneal	 injection	 of	 0.07	 mg/kg	 Y-27632	 into	
ENCC	 +	 Y-27632	 group,	 every	 alternate	 day.	Normal	 saline	was	 in-
jected	 into	 the	ENCC-only	 group	 and	 control	 group	using	 the	 same	
protocol. Three weeks after the transplantation, the rats were sacri-
ficed	and	colon	segments	were	isolated,	fixed,	and	paraffin-embedded	
in a longitudinal orientation.
2.10 | Immunohistochemistry and 
immunofluorescence
Colon	 segments	were	 analyzed	with	DAB	 immunohistochemistry	
of	 PGP9.5	 and	 Tuj1,	 and	 immunofluorescence	 of	 GFP	 and	 Tuj1.	
ENCCs	in	the	in	vitro	experiment	were	stained	for	immunofluores-
cence	 of	 p75	 neurotrophin	 receptor	 (p75	NTR),	 nestin,	 and	 neu-
ronal	nuclei	(NeuN).
Paraffin-embedded	sections	were	subjected	to	dewaxing,	rehy-
dration,	and	antigen	retrieval	using	citrate	(Beyotime	Biotechnology,	
P0081).	The	 immunohistochemistry	procedure	was	performed	ac-
cording	 to	 the	 manufacturer's	 instruction	 of	 SP	 Rabbit	 &	 Mouse	
HRP	 Kit	 (Cwbio,	 CW2069).	 Immunofluorescence	 staining	 started	
Antibody Brand Cat# RRID Application dilution
anti-p75	NTR Abcam ab8874 AB_306827 IF 1:200
anti-Nestin Abcam ab11306 AB_1640723 IF 1:200
anti-β-III Tubulin 
(Tuj1)
Genetex GTX631836 AB_2814952 IF 1:200
anti-GFAP Abcam ab33922 AB_732571 IF 1:200
anti-NeuN Abcam ab177487 AB_2532109 IF 1:200
anti-GFP Abcam ab6556 AB_305564 IF 1:500
Goat	anti-Rabbit	IgG	
H&L	Alexa	Fluor	
488
Abcam ab150077 AB_2630356 IF 1:400
Goat	anti-Mouse	IgG	
H&L	Cy3
Abcam ab97035 AB_10680176 IF 1:400
anti-PGP9.5 Genetex GTX109637 AB_1952497 IHC 1:200
anti-β-III Tubulin 
(Tuj1)
Genetex GTX631836 AB_2814952 IHC 1:200
anti-GFAP Abcam ab33922 AB_732571 WB 1:1000
anti-β-III Tubulin 
(Tuj1)
Genetex GTX631836 AB_2814952 WB 1:1000
anti-β-actin Abcam ab8226 AB_306371 WB 1:2000
EasyBlot	anti-Mouse	
IgG	(HRP)
Genetex GTX221667-01 AB_10728926 WB 1:1000
EasyBlot	anti-Rabbit	
IgG	(HRP)
Genetex GTX221666-01 AB_10620421 WB 1:2000
GFAP,	glial	fibrillary	acidic	protein.
NeuN, neuron nuclear protein.
P75NTR,	P75	neurotrophin	receptor.
PGP9.5,	protein	gene	product	9.5.
Tuj1, β-III-tubulin.
TA B L E  1  Antibodies	List	of	antibodies	
used	in	this	experiment
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from	permeabilization	using	0.1%	Triton	X-100	in	PBS	for	15	minutes	
and	followed	by	three	times	washing	in	PBS.	After	this,	goat	serum	
(Beyotime,	C0265)	was	used	to	block	for	1	hour.	Antibodies	(listed	in	
Table.	1)	and	DAPI	reagent	were	incubated	accordingly.	All	the	slides	
were mounted with antifade mounting medium.
2.11 | Cell lysis and Western blot
Differentiated	ENCCs	 (see	2.4)	were	 lysed	on	 ice	 in	RIPA	buffer	
(Beyotime	Biotechnology,	P0013C)	containing	1%	protease	inhibi-
tor	(Roche,	04693116001).	Protein	quantification	was	performed	
using	the	BCA	Protein	Assay	Kit	(Beyotime	Biotechnology,	P0012).	
Then, 20 µg cell lysate of each sample was boiled after adding 
laemmli	 buffer,	 loaded	 onto	 an	 SDS-PAGE	 gel,	 and	 transferred	
to	 a	PVDF	membrane.	Evaporated	milk	 (5%)	 in	TBS	was	used	as	
a	 blocking	 buffer.	 After	 incubation	 with	 primary	 and	 secondary	
antibodies,	membranes	were	developed	with	Immobilon	Western	
chemiluminescent	HRP	substrate	kit	(Millipore,	WBKLS0500).	The	
antibodies used are listed in Table 1.
2.12 | Statistical analysis
For statistical analysis, student t	 test	 and	 one-way	 ANOVA	were	
used to determine differences between each treated group and the 
control	group.	Gaussian	distribution	with	equal	variance	was	tested.	
Welch's	correction	was	applied	in	cases	where	statistical	different	
variances were detected. The bodyweight of all rats was analyzed 
using	two-way	ANOVA	test.
3  | RESULTS
3.1 | Cultured neurospheres expressed P75NTR and 
nestin and can be differentiated into neurons and glia
Irregular free-floating neurospheres started to form 2 days after 
seeding the primary culture. On day seven, larger and more compact 
neurospheres	were	observed	 (Figure	1A).	 Subsequent	 generation	of	
neurospheres	was	obtained	by	subculturing	(Figure	1B).	Interestingly,	
as	 shown	 in	 Figure	 1B,	 7	 days	 after	 splitting,	 cell	 clusters	 obtained	
F I G U R E  1  Primary	culture	of	ENCC	neurosphere	and	immunofluorescence	staining	(A)	Irregular	free-floating	ENCC	neurospheres	
appeared	on	day	two.	Larger	and	compacted	neurospheres	formed	on	day	seven.	B,	7	d	after	splitting,	cell	clusters	obtained	by	gentle	
pipetting	(left)	showed	better	neurosphere	formation	than	single-cell	suspension	obtained	via	trypsinization	with	repeated	pipetting	
(right).	The	latter	were	more	likely	to	attach	and	demonstrate	morphologic	changes.	C,	Immunofluorescence	staining	showed	considerable	
expression	of	neural	stem	cell	markers	P75	NTR	and	Nestin	in	neurospheres.	D,	By	differentiation	induction,	Tuj1	positive	or	GFAP	positive	
cells were derived, indicating neuron and glia. Scale bar, 100 µm
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from	 gentle	 pipetting	 (left)	 showed	 better	 neurospheres’	 formation	
than single-cell suspension obtained from trypsinization with repeated 
pipetting	(right).	This	stressed	the	importance	of	minimizing	the	dura-
tion of incubation with dissociative reagents and gentle pipetting.
Immunofluorescence	for	neural	stem	cell	markers	P75	neurotro-
phin	 receptor	 (P75NTR)	 and	 nestin	 showed	 double-positive	 stain-
ing	 of	 the	 neurospheres	 (Figure	 1C).	 By	 inducing	 differentiation,	
cells	 became	beta-III-tubulin	 (Tuj1)	 positive	or	 glial	 fibrillary	 acidic	
protein	 (GFAP)	 positive,	 indicating	 neuronal	 or	 glial	 differentia-
tion	(Figure	1D).	Cells	co-expressed	with	Tuj1	and	GFAP	were	also	
showed but the mechanism remained unclear. Premature stage of 
the	cells	or	multi-differentiation	potential	could	be	plausible	expla-
nation,	 while	 further	 studies	 required.23,24 Taken together, these 
results	showed	that	we	were	able	to	efficiently	generate	ENCC	neu-
rospheres, which could be used for following analyses.
3.2 | RhoA/ROCK inhibitors increased 
ENCCs viability
To	 assess	 the	 effect	 of	 inhibiting	 the	 RhoA/ROCK	 pathway	 on	
ENCC	 viability,	 cells	 were	 treated	 with	 different	 concentrations	
of	 RhoA	 inhibitor	 CCG-1423,25	 ROCK	 inhibitor	 Y-27632	 dihydro-
chloride,26	and	ROCK2	inhibitor	SR-3677,27 and then subjected to 
a viable cell counting assay. Since this assay was directly propor-
tional to the number of living cells, it could reflect how cell grew 
F I G U R E  2  Viability,	morphology,	and	apoptosis	of	ENCCs	responded	to	RhoA/ROCK	inhibitors	(A)	Results	of	Cell	Counting	Kit-8	test	
normalized by non-treated control cells showed different effects on cell viability and growth by each inhibitor at different concentrations. 
B,	treatment	with	10	µmol/L	Y-27632	and	1	µmol/L	SR-3677	showed	a	significant	increased	viability	of	ENCC	compared	to	PBS	treated	
control,	and	no	significant	difference	was	detected	upon	treatment	with	10	µmol/L	CCG-1432	(t	test,	X	±	SD,	Box-&Whiskers	chart,	n	=	24,	
10,	10,	10).	C,	Representative	images	of	ENCCs	grown	in	different	inhibitor	groups	after	5	d	of	treatment.	The	CCG-1432	group	showed	
similar morphology to that of the control, the other two groups showed some morphological changes of attachment. Scale bar, 100 µm. 
D,	Quantification	of	the	number	of	neurospheres	(shown	in	panel	C)	showed	no	differences	between	groups	(t	test,	X	±	SD,	n	=	11,	10,	10,	
10).	E,	Quantification	of	the	number	of	attached	neural	cells	(shown	in	panel	C)	shows	that	significant	more	cells	were	attached	in	groups	
treated	with	Y-27632	or	SR-3677	(t	test,	X	±	SD,	n	=	11,	10,	10,	10).	F,	G,	Flow	cytometry	measurements	of	apoptosis	showed	no	significant	
difference	between	groups	(t	test,	X	±	SD,	n	=	3)
TA B L E  2  Statistical	results	List	of	statistical	results	of	ENCCs	in	vitro	experiment
Fig. Assay t-test Control CCG-1423 10 µmol/L Y-27632 10 µmol/L SR-3677 1 µmol/L
Figure 2B CCK-8	kit X	±	SD 1.00	±	0.0643 1.058 ± 0.1001 1.39 ± 0.2905 1.45	±	0.5293
P-value - .0517 .0021** .0247*
Figure 2D Neurosphere number X	±	SD 21.45	±	8.595 21.20	±	7.052 18.10	±	6.437 16.70	±	4.001
P-value - .9420 .3281 .1269
Figure	2E Attached	neural	cells X	±	SD 45.45	±	12.44 47.30	±	10.87 148.1	±	54.16 163.7	±	68.91
P-value - .7227 .0002*** .0004***
Figure	2G Apoptosis	assay X	±	SD 29.14	±	15.12 19.20 ± 5.902 24.05	±	12.16 19.57	±	4.028
P-value - .3484 .6732 .3492
Figure	3C Differentiation
Cell	number
X	±	SD 13.84	±	1.514 13.24	±	4.336 86.71	±	19.38 90.66	±	23.56
P-value - .2605 <.0001**** <.0001****
Figure 3D Differentiation
NeuN/All
X	±	SD 0.6987	±	0.1321 0.7562	±	0.0661 0.8890	±	0.0704 0.8304	±	0.0445
P-value - .2749 .0015** .0181*
Figure 3F WB	Tuj1/β-actin X	±	SD 1.000 ± 0.000 1.065	±	0.0796 2.141	±	0.3022 2.487	±	0.6865
P-value - .2948 .0028** .0199*
Figure	3G WB	GFAP/β-actin X	±	SD 1.000 ± 0.000 0.9078	±	0.2225 1.219 ± 0.2150 1.306	±	0.2034
P-value - .3565 .0316* .0042**
Figure 3I Migration	assay X	±	SD 1.000	±	0.3645 0.9147	±	0.3062 2.905	±	1.647 1.403	±	1.373
P-value - .4040 .00004**** .2158
CCK-8,	Cell	Counting	Kit-8.
NeuN, neuron nuclear protein.
Tuj1, β-III-tubulin.
GFAP,	glial	fibrillary	acidic	protein.
*P < .05. 
**P < .01. 
***P < .001. 
****P < .0001. 
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and	proliferated.	Results	showed	that	treatment	with	CCG-1423	did	
not	affect	 the	number	of	 live	cells,	while	 treatment	with	Y-27632	
and	SR-3677	showed	a	remarkable	increase	when	compared	to	con-
trol	 (Figure	2A,	B;	Table	2).	Both	Y-27632	and	SR-3677	enhanced	
viable	cell	numbers	at	a	concentration	of	0.1	µmol/L,	with	a	peak	
at	10	µmol/L	for	Y-27632	and	1	µmol/L	for	SR-3677,	respectively.	
Upon taking the peak value of each group, significant increase 
caused	by	Y-27632	and	SR-3677	was	confirmed	(Figure	2B;	Table	2).	
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Based	on	these	findings,	the	optimal	doses,	10	µmol/L	for	Y-27632	
and	1	µmol/L	 for	SR-3677,	were	 chosen	 for	 further	experiments.	
Although	 no	 significant	 difference	was	 observed	 upon	 treatment	
with	CCG-1423,	we	decided	to	include	this	inhibitor	at	a	concentra-
tion	of	10	µmol/L	in	further	experiments.
For	morphology	features,	ENCCs	neurospheres	showed	various	mor-
phological	behaviors	upon	treatment	with	different	inhibitors	(Figure	2C).	
As	quantified	by	the	number	of	neurospheres	and	attached	cells,	CCG-
1423	showed	similar	 results	as	 that	observed	 in	control.	However,	 the	
Y-27632	and	SR-3677	groups	revealed	comparable	neurosphere	amounts	
but	significant	higher	induction	of	cell	attachment	(Figure	2D,	E;	Table	2).
In order to detect whether the different inhibitors influenced 
apoptosis,	 FACS	analysis	with	Annexin	V:	PE	Apoptosis	Detection	
Kit	 was	 used	 (Figure	 2F).	 No	 significant	 difference	 was	 detected	
between	 the	 three	 treated	groups	and	 the	control	 (Figure	2G).	All	
statistical results have been shown in Table 2.
3.3 | RhoA/ROCK inhibitors induced the 
differentiation and migration of ENCCs
ENCC	possesses	vital	 features	 to	differentiate	 into	both	neurons	and	
glia,	 which	 is	 essential	 for	 the	 formation	 of	 a	 proper	 ENS	 network.	
Therefore, it is important to investigate whether the inhibitors influ-
ence	the	differentiation	ability	of	single	cells	obtained	from	ENCCs.	To	
study	 this,	 cells	were	 treated	with	 10	µmol/L	CCG-1423,	 10	µmol/L	
Y-27632,	 and	 1	 µmol/L	 SR-3677	 for	 72	 hours,	 accompanied	 by	 2%	
FCS	stimulation.	Our	results	showed	that	in	all	groups,	ENCC	differen-
tiation	occurred,	which	could	be	observed	by	acquiring	a	 longitudinal	
shape	 and	 emergence	 of	 neurites	 (Figure	 3A).	 Immunofluorescence	
staining	showed	the	expression	of	the	neuronal	marker	neuronal	nuclei	
(NeuN)	 in	differentiated	cells	 (Figure	3B).	Quantification	of	differenti-
ated	cells	numbers	 (Figure	3A,	C;	Table	2)	and	percentages	of	NeuN+ 
cells	(Figure	3B,	D;	Table	2)	showed	a	significant	increase	in	the	number	
of	cells	that	were	differentiated	upon	treatment	with	either	Y-27632	or	
SR-3677,	compared	to	cells	treated	with	CCG-1423	and	the	PBS	treated	
controls.	 In	 addition,	Western	 blot	 analysis	 confirmed	 these	 findings	
showing	increased	expression	of	Tuj1	and	GFAP	upon	treatment	with	ei-
ther	Y-27632	or	SR-3677	(Figure	3E-G;	Table	2).	According	to	the	results,	
Y-27632	and	SR-3677	could	not	only	accelerate	the	total	number	of	dif-
ferentiated cells by promoting differentiation ability, but also increase 
the proportion of differentiated neurons and glial cells.
To	analyze	the	effect	of	 the	RhoA/ROCK	 inhibitors	on	cell	mi-
gration, a trans-well assay was performed where the three different 
inhibitors were added to both the upper and bottom chambers. Our 
results	showed	that	treatment	with	Y-27632	significantly	increased	
the	migration	rate	of	ENCCs,	while	the	other	two	inhibitors	had	no	
effect	(Figure	3H,	I).	Meanwhile,	we	noticed	that	cells	treated	with	
SR-3677	 displayed	 a	 heterogeneous	 migration	 pattern,	 in	 which	
regions of cell aggregated and empty regions were randomly dis-
tributed	 in	 the	 membrane,	 exhibiting	 a	 large	 standard	 deviation	
(Figure	3H,	I;	Table	2).	The	statistical	results	of	all	the	above	assays	
are shown in Table 2.
3.4 | ENCC transduction required a proper 
lentiviral multiplicity of infection (MOI) 
to balance transduction efficiency and 
neurosphere morphology
For cell-based therapy, labeling the cells to be grafted could en-
sure continuous tracking after transplantation in the animal model. 
Lentiviral	 transduction	enables	efficient,	 stable,	 and	 long-term	 labe-
ling	of	ENS	stem	cells	 that	 is	 retained	after	 transplantation	 into	 the	
gut in vivo28	and	does	not	 induce	toxicity.29	Moreover,	the	 lentiviral	
approach could offer the possibility to transfect with a construct con-
taining	specific	genes	of	interest	in	future	experiments,	such	as	genes	
containing mutations or rescue constructs for gene therapy.28
For	our	experiments,	we	decided	to	use	a	GFP-expressing	lentiviral	
construct and started by determining the optimal multiplicity of infec-
tion	(MOI)	among	5×,	25×,	125×,	and	250×.	Cells	were	inspected	micro-
scopically	to	assess	their	morphological	features	and	analyzed	by	FACS	
to determine the transduction efficiency. Transduction with the lowest 
amount	of	virus,	5×	MOI,	provided	insufficient	labeling,	whereas	trans-
duction	with	125×	MOI	and	250×	MOI	influenced	the	shape	of	neuro-
spheres	as	they	appeared	elongated	(Figure	4A).	25×	MOI	seemed	to	be	
the	optimal	lentiviral	concentration	that	resulted	in	adequate	transduc-
tion	efficiency	(85%	GFP-positive	ENCCs),	while	maintaining	the	original	
shape	of	ENCCs	(Figure	4B,	C).	After	transduction	with	25×	MOI,	neu-
rospheres	were	collected,	cultured,	and	further	differentiated.	We	were	
able	to	see	that	the	GFP	gene	could	be	successfully	transferred	to	the	
daughter	cells	and	retained	through	differentiation	process	(Figure	4D),	
indicating	 that	 good	 labeling	 of	 ENCCs	 could	 be	 obtained	 with	 this	
approach.
F I G U R E  3  Differentiation	and	migration	of	ENCCs	responded	to	RhoA/ROCK	inhibitors	(A,	B)	The	differentiation	behavior	of	ENCCs	
under	light	microscopy	and	immunofluorescence	staining	of	neuronal	nuclei	(NeuN).	C,	The	number	of	differentiated	ENCCs	quantified	per	
light	microscope	field	(shown	in	panel	A).	ENCCs	treated	with	Y-27632	or	SR-3677	showed	a	significantly	more	differentiated	cells	compared	
to	the	control	group	and	the	group	treated	with	CCG-1432	(t	test,	X	±	SD,	n	=	12).	D,	The	percentage	of	NeuN+	cells	quantified	per	field	
of	view	(shown	in	panel	B)	was	higher	in	groups	treated	with	Y-27632	and	SR-3677	than	in	the	other	two	groups	(t	test,	X	±	SD,	n	=	9).	E,	
Western	blot	analysis	of	differentiated	ENCCs	showed	increased	of	Tuj1	and	GFAP	protein	expressed	in	ENCCs	treated	with	Y-27632	and	
SR-3677	compared	to	control	and	CCG-1423	group.	F,	Quantification	of	the	Western	blot	quantification	of	Tuj1	relative	to	β-actin	(t test, 
X	±	SD,	n	=	3).	G,	Quantification	of	the	Western	blot	of	GFAP	relative	to	β-actin	(t	test,	X	±	SD,	n	=	6).	H,	Trans-well	migration	assay	assessed	
by	the	number	of	ENCCs	that	migrated	through	the	chamber	membrane	and	stained	with	gentian	violet.	The	distribution	of	migrated	ENCCs	
showed	a	homogenous	pattern	in	the	control,	CCG-1432,	and	Y-27632	groups,	while	a	non-uniform	pattern	was	observed	in	the	SR-3677	
group.	I,	Quantification	of	migrated	cells	per	imaged	field	normalized	by	control	showed	a	significant	increase	in	Y-27632	treated	group	(t 
test,	X	±	SD,	n	=	24,	21,	21,	20).	Scale	bar,	100	µm
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3.5 | Y-27632 improved the efficiency of ENCC 
transplantation in a hypoganglionic rat model
Considering	that	the	ROCK	inhibitor	Y-27632	gave	the	most	comprehen-
sive	results	in	our	in	vitro	assays	from	the	three	RhoA/ROCK	inhibitors	
tested,	we	expected	that	Y-27632	would	have	the	potential	to	increase	
the	efficiency	of	ENCC	transplantation	in	vivo.	To	test	this	hypothesis,	
we	performed	ENCC	transplantation	in	an	inducible	hypoganglionic	rat	
model	established	by	30	minutes	 incubation	with	0.1%	benzalkonium	
chloride	(Figure	5A).	 It	 is	a	widely	used	non-genetic	modulated	HSCR	
model, and ideal hypoganglionic segments could be achieved within a 
limited time.30,31
To ensure that a hypoganglionic gut was induced, histologic eval-
uation	of	the	BAC-treated	segment	was	performed	2,	4,	and	6	weeks	
later.	At	these	three	time	points,	stenosis	of	the	treated	segment,	and	
proximal	dilation	was	macroscopically	observed	in	the	model	(Figure	5B).	
Immunostaining	 of	 Tuj1	 and	 PGP9.5	 was	 performed	 as	 well,	 and	 it	
showed	reduction	of	neural	cells	after	treatment	(Figure	5C).	Quantified	
results	 showed	 a	 significant	 decrease	 in	 the	 number	 (Figure	 5D,	
X	±	SEM,	 control	5.000	±	0.4629,	2	weeks	2.636	±	0.2787,	4	weeks	
3.400	±	0.2667,	6	weeks	3.600	±	0.4522;	P-value: P-2	weeks=.0002***,	
P-4	 weeks=.0063**,	 P-6	 weeks=.0480*)	 and	 size	 (Figure	 5E	 ,	
X	±	SEM,	control	1.000	±	0.1520,	2	weeks	0.5189	±	0.0862,	4	weeks	
0.5311	±	0.0763,	6	weeks	0.5025	±	0.0703;	P-value: P-2	weeks=.0078**,	
P-4	weeks	=	.0078**,	P-6	weeks=.0044**)	of	the	ganglia	after	BAC	treat-
ment. Thus, hypoganglionic models were successfully induced and could 
be	used	for	ENCC	transplantations.
Transplantation	 experiments	 had	 a	 total	 duration	 of	 6	 weeks	
(Figure	6A),	which	consisted	of	the	establishment	of	the	hypogan-
glionic	 rat	model	 (3	weeks),	 and	 in	parallel	 the	culturing	and	GFP-
labeling	of	ENCCs.	Then,	at	day	21,	ENCCs	were	transplanted	into	
the	muscle	layer	by	injections	at	the	clock	positions	3,	6,	9,	and	12	
(Figure	6B),	followed	by	postoperative	treatment	with	either	PBS	or	
Y-27632	every	 alternate	 day	 until	 day	42.	During	 the	 experiment,	
the bodyweight of all the rats was measured every other day and 
analyzed as the relative ratio of weight change to initial weight 
(Figure	6C).	ANOVA	test	revealed	that	the	bodyweight	changed	over	
time	(P	<	 .0001)	showing	two	obvious	decreases	after	two	surger-
ies.	However,	 between	 the	 three	groups,	no	 significant	difference	
(P=.7349)	was	found.
Three	weeks	after	transplantation,	17	rats	from	the	control	group,	
18	rats	in	the	ENCC-only	group,	and	18	rats	in	the	ENCC	+	Y-27632	
F I G U R E  4  ENCCs	labeled	by	lentiviral	transduction	of	GFP	(A)	Lentiviral	transduction	of	GFP	into	ENCCs	using	different	multiplicity	of	
infection	(MOI)	showed	that	25×	MOI	showed	the	proper	ratio	to	balance	transduction	efficiency	and	retention	of	proper	morphology.	5×	
MOI	was	insufficient	for	labeling,	while	125×	and	250×	MOI	would	trigger	changes	to	cell	shape.	B,	Negative	control	for	flow	cytometry	
analysis	of	transduction	efficiency.	C,	Transduction	efficiency	quantification	by	flow	cytometry	showed	that	upon	transduction	with	25×	
MOI,	85.87%	of	the	ENCCs	were	GFP-positive.	D,	Representative	image	of	transduced	ENCCs	after	second	passage	demonstrated	that	GFP	
was	incorporated,	passed	on	to	next-generation	cells,	and	retained	through	the	differentiation	process.	Scale	bar,	100	µm
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group survived. Seven rats died due to anesthesia intolerance or 
wound	biting	 or	 bleeding.	H&E	 staining	 of	 the	 transplanted	 colon	
segment	 in	ENCC-only	and	ENCC	+	Y-27632	groups	showed	slight	
cell	aggregation	at	the	injection	site	(Figure	6D).
To	unravel	the	effect	of	ROCK	inhibitor	on	ENCC	transplantation,	
double-immunofluorescent	staining	of	GFP	and	Tuj1	was	performed.	
GFP+	 cells	 were	 scored	 to	 determine	 the	 number	 of	 exogenous	
(grafted)	ENCCs,	and	GFP−/Tuj1+ cells were scored to determine other 
neural	cells	which	consisting	mostly	of	the	endogenous	ENS	cells	and	
a	 fraction	of	unlabeled	graft	ENCCs	 (Figure	6E).	Since	Y-27632	was	
injected intraperitoneally, all above-mentioned cells are subjected to 
this	 treatment.	Grafted	ENCCs	survived	and	migrated	 longitudinally	
and/or laterally into the mucosa, submucosa and muscle layer in both 
ENCC-only	 and	 ENCC	 +	 Y-27632	 group.	 However,	 a	 significantly	
broader	distribution	of	GFP+	cells	was	detected	in	the	ENCC	+	Y-27632	
group, both in the injection site and adjacent region. Fluorescence 
density	was	scored	 for	quantitative	analysis	 (Figure	6F,	X	±	SEM	of	
GFP+,	ENCC-only	1.538	±	0.1576,	ENCC	+	Y-27632	2.315	±	0.3148,	
P=.0007***).
As	 to	 GFP−/Tuj1+	 cells,	 quantification	 of	 the	 fluorescence	
showed	 comparable	 results	 of	 control	 and	 ENCCs-only	 groups,	
but	 a	 significantly	 higher	 density	 in	 the	 ENCCs	 +	 Y-27632	 group.	
(Figure	6F,	X	±	SEM	of	GFP−/Tuj1+,	control	1.000	±	0.0801,	ENCCs-
only	0.9094	±	0.1187,	ENCCs	+	Y-27632	1.664	±	0.2120,	P control 
vs	 ENCCs-only	 =.5310,	 P	 control	 vs	 ENCCs	 +	 Y-27632	 =.0073**,	
P	 ENCCs-only	 vs	 ENCCs	 +	 Y-27632	 =.0041**).	 It	 suggested	 that	
Y-27632	affected	not	only	the	graft	ENCCs,	but	also	the	endogenous	
ENS	with	increased	distribution.
To verify these findings, we performed immunostainings using 
the	neuronal	marker	Tuj1	and	the	pan-neuronal	marker	PGP9.5	(es-
sential	for	HSCR	diagnosis),	and	also	performed	separate	 immuno-
fluorescence	of	GFP	 (Figure	S1A,	B).	 The	density	of	 each	 staining	
was	scored	to	evaluate	total	neural	cells	or	graft	ENCCs,	and	similar	
results	as	significantly	higher	density	of	PGP9.5,	Tuj1,	and	GFP	were	
obtained	in	the	ENCC	+	Y-27632	group	compared	to	others	(Figure	
S1C-D).
Together,	 these	 results	 showed	 that	 Y-27632	 could	 enhance	
the	distribution	of	 the	exogenous	grafted	ENCCs	and	also	benefit	
endogenous	 ENS	 restoration	 thereby	 providing	 an	 auxiliary	 con-
tribution.	These	 findings	 implied	 that	ROCK	 inhibitor	Y-27632	has	
the	potential	to	 increase	the	efficiency	of	ENCC-based	therapy	by	
enhancing cell survival, neural differentiation, and migratory ability.
4  | DISCUSSION
In	 this	 study,	 we	 demonstrated	 the	 positive	 influence	 of	 ROCK	
signaling	pathway	 inhibitors	on	ENCC	viability	 and	growth,	 differ-
entiation,	and	migration	 in	vitro.	We	also	showed	 increased	ENCC	
transplantation	efficiency	by	inhibiting	the	ROCK	signaling	pathway	
in an induced hypoganglionic rat model, indicating the accelerating 
effect	on	ENCC-based	therapy.
Cell-based	therapy	is	considered	to	be	the	most	promising	ther-
apeutic	 approach	 for	 HSCR,	 especially	 since	 several	 studies	 have	
shown	that	ENCC-based	transplantation	could	successfully	restore	
the	ENS.5-7	However,	this	approach	has	limitations,	such	as	immune	
reactions, inflammation, poor survival, limited migration, and apop-
tosis	of	the	transplanted	ENCCs.	To	solve	these	issues,	the	cells	used	
for transplantation must be carefully considered. Both embryonic 
and	postnatal	 ENCC	have	been	 applied	 for	 therapeutic	 transplan-
tation	 research.	 Although	 using	 postnatal	 and	 adult	 ENS	 cells	 for	
transplantation gave promising results,7,32	 ENS	 stem/progenitor	
cells undergo a decline in their proliferative potential, self-renewal 
and multi-lineage differentiation capacity from fetal to postnatal 
stages,33	and	also	in	ability	to	form	ENS.	Therefore,	 it	may	be	bet-
ter	to	aim	at	replicating	the	embryonic	ENS	stage	rather	than	using	
postnatal	ENS	stem/progenitor	cells	for	ENS	cell	therapies	consider-
ing these features,34	yet	this	requires	further	evaluation	to	balance	
other influencing advantages and disadvantages of both cell types. 
Currently,	induced	pluripotent	stem	cells	(iPSCs)	are	also	considered	
to be a promising source, as they are autologous, easy to generate 
and	expand.	And	interestingly,	ROCK	inhibitor	has	also	been	widely	
used	 during	 iPSCs	 culture	 to	 promote	 growth.35	 Although	 differ-
entiation	 protocols	 for	 derivation	 of	 neural	 cells	 from	 iPSC	 have	
been established by various research groups based on the modu-
lation of known inductive signals,36-38 neural cells obtained were 
F I G U R E  5  Establishment	and	evaluation	of	the	induced	hypoganglionic	rat	model	(A)	The	hypoganglionic	rat	model	was	established	by	
incubating	the	target	colon	segment	in	0.1%	benzalkonium	chloride	for	30	min.	B,	At	2,	4	and	6	wks	after	surgery,	the	rats	showed	stenosis	
change	of	the	treated	segment	and	dilation	of	the	proximal	colon.	C,	Immunohistochemical	staining	of	the	treated	segments	by	Tuj1	and	
PGP9.5	showed	hypoganglionosis,	which	was	quantified	in	panel	D	and	E.	Scale	bar,	100	µm.	D,	E,	Ganglion's	number	and	size	reduced	at	2,	
4,	and	6	wks	after	BAC	treatment	(t	test,	X	±	SEM,	n	=	8,	11,	10,	10)
F I G U R E  6  ENCC	transplantation	in	the	hypoganglionic	rat	model	shows	increased	grafting	ability	upon	treatment	with	Y-27632.	
A,	Overview	of	the	experimental	timeline.	The	duration	was	6	wks,	which	consisted	of	rat	model	establishment,	ENCCs	culture,	GFP-
labeling,	ENCCs	transplantation	by	injections	into	the	muscle	layer,	and	postoperative	treatment	with	PBS	or	Y-27632.	B,	Transplantation	
was	performed	by	3,	6,	9,	and	12	clockwise	injections	into	the	muscle	layer	of	the	segment	center,	shown	as	black	arrows.	C,	Bodyweight	
measured by relative change ratio to initial weight at day 0 showed changes over time and obvious decreases after the two operations. No 
significant	difference	was	found	between	the	groups	(ANOVA	test,	n	=	17,	18,	18).	D,	H&E	staining	of	the	transplanted	segment	in	ENCC-
only	group	and	ENCC	+	Y-27632	group	showed	slight	cell	aggregation	at	the	injection	site	but	otherwise	no	obvious	structural	changes.	
Scale	bar,	200	µm.	E,	Double-IF-staining	of	GFP	and	Tuj1	in	transplanted	tissue.	GFP+	cells	were	indicated	by	the	*,	and	GFP-/Tuj1+ cells were 
indicated by the arrows. Scale bar, 100 µm. F, Fluorescence densities were scored and showed a significant increase in presence of both 
GFP+	and	GFP-/Tuj1+	cells	in	the	ENCC	+	Y-27632	group	(t	test,	X	±	SEM,	n	=	17,	18,	18)
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usually heterogeneous with variety of neurogenic fate potential.39 
Therefore,	it	is	still	challenged	to	develop	fully	functioning	ENS	cells	
from human pluripotent stem cells, and a standard necessitated to 
evaluate	between	different	protocols	and	derived	ENS	cells.
Another	 feasible	 option	 is	 to	 treat	 ENCCs	 with	 compounds	
during	 transplantation	 and	 homing.	 For	 example,	 serotonin	 and	
5-HT4 receptor agonists have been shown to increase the number 
of	grafted	ENCCs,	 leading	to	better	transplantation	outcomes.40,41 
Local	injection	of	caspase-1	inhibitor	was	also	reported	to	enhance	
cell survival after transplantation into the gastric wall.42	Pepstatin	A	
was reported as a candidate therapeutic drug using on human plu-
ripotent	stem	cell-based	platform,	presenting	a	first	example	of	cell-	
and	drug-based	strategies	for	the	treatment	of	HSCR.43 In our study, 
we	 focused	 on	 the	 inhibition	 of	 the	 RhoA/ROCK	 pathway	 during	
ENCC-based	transplantation	and	we	showed	for	the	first	time	that	
the	ROCK	 inhibitor	Y-27632	had	a	positive	 influence	on	ENCCs	 in	
vivo.
The	 RhoA/ROCK	 pathway	 consists	 of	 RhoA	 and	 downstream	
isomers,	ROCK1,	and	ROCK2.	It	has	been	identified	to	play	a	role	in	
neural	crest	specification,	through	ROCK	and	its	downstream	target	
non-muscle	Myosin	II.44	Relevant	to	our	work,	Y-27632	has	been	re-
ported to promote neural crest generation and differentiation in a 
co-culture system with mouse embryonic fibroblasts.45	A	possible	
mechanism	of	specification	might	go	through	YAP	which	has	been	
implicated in neural differentiation.44	 Alternatively,	 modulating	
ROCK	might	change	Wnt,	Bone	morphogenetic	proteins	 (BMP),	or	
FGF	signaling	pathways	that	are	known	to	control	neural	crest	de-
velopment.44,46	According	to	our	results,	ROCK	inhibitors	could	in-
crease	ENCC	viability,	differentiation,	and	migration,	while	the	RhoA	
inhibitor	(CCG-1423)	showed	no	effect.	This	indicates	the	existence	
of	a	direct	effect	of	downstream	ROCK	isomers	and	a	plausible	mul-
tiple-pass	regulation	upon	inhibition	of	RhoA.
Y-27632	 is	 known	 to	 inhibit	ROCK	kinase	activity,	 suppressing	
the downstream phosphorylation cascade of myosin light chain 
phosphatase	(MLCP)	and	LIM	kinase	(LIMK).12 Both proteins are in-
volved in actin cytoskeletal dynamics and are important for smooth 
muscle contraction. It is well known that intestinal motility relies on 
the	interaction	between	the	ENS	and	the	smooth	muscle.	However,	
how	exactly	one	influences	the	other	is	still	unclear.	A	recent	study	
identified abnormal levels of γ-smooth	 muscle	 actin	 in	 HSCR	 pa-
tients.47	Since	the	RhoA/ROCK	pathway	is	known	to	be	essential	for	
smooth	muscle	contraction	but	also	for	axonal	growth,	it	is	tempting	
to	speculate	that	the	RhoA/ROCK	pathway	is	the	basis	of	this	neu-
ral-muscle relationship.
ROCK	isoforms	are	ubiquitously	expressed	throughout	mamma-
lian embryogenesis and in all adult tissues.48 In the large and small 
intestines,	ROCK1	and	ROCK2	are	identified	in	both	the	epithelium	
and smooth muscle layers.49	In	the	submucosa,	they	are	expressed	
in	nerve	cells	and	cell	bodies	of	interstitial	cells	of	Cajal	(ICCs).50 The 
RhoA/ROCK	 pathway	 can	 be	 activated	 by	 various	 membrane	 re-
ceptors	upon	binding	of	extracellular	cytokines,	and	in	turn,	it	could	
influence	other	pathways.	Therefore,	 in	HSCR	patients,	 Integrin,51 
collagen,9,10	transforming	growth	factor	(TGF-β),52	and	BMPs53 are 
plausibly	related	to	ROCK	expression	level	as	the	regulated	factors.	
Furthermore,	 ROCK	 expression	 in	 the	 aganglionic	 gut	 is	 essential	
for the following application of inhibitors to patients. Unfortunately, 
we	could	not	confirm	the	expression	due	to	the	non-specificity	of	
the	 antibodies	 used	 (data	 not	 shown).	 However,	 previous	 studies	
showed	on	the	one	hand	increased	ROCK1	expression	in	the	agan-
glionic bowel of an Ednrb(−/−) rat model,21 but on the other hand 
reduced	expression	of	ROCK1	in	the	aganglionic	bowel	of	HSCR	pa-
tients.50	The	discrepancy	between	these	findings	might	be	explained	
by differences between humans and mice, but problems with the 
antibodies	might	also	be	an	explanation	of	the	differences	observed.	
Another	issue	might	be	the	different	genetic	backgrounds	or	differ-
ent	micro-environments	of	 the	ENS	 in	 the	human	and	mouse	gut.	
Clearly,	additional	studies	are	needed	to	determine	the	expression	
of	ROCK	in	HSCR	patients.
Apart	from	ENS,	Y-27632	has	been	reported	as	potential	thera-
peutic agents in a variety of diseases including liver fibrosis,54 acute 
respiratory distress syndrome,55 renal interstitial inflammation and 
fibrosis, long-term renal graft survival.56	 Although	 not	 much	 has	
been	mentioned	about	the	drawbacks	of	Y-27632,	the	broad	applica-
tion pointed out that it will affect various tissues and organ systems, 
which	should	be	considered	for	the	use	of	Y-27632	in	HSCR.
5  | CONCLUSION
Our	 study	 showed	 that	 inhibition	 of	 ROCK	 by	 Y-27632	 could	 not	
only	 increase	 the	growth,	differentiation,	 and	migration	of	ENCCs	
in	vitro,	but	also	improve	the	efficiency	of	ENCC	transplantation	via	
acceleration	 on	 graft	 ENCCs	 and	 endogenous	 ENS,	 leading	 to	 an	
improved	 outcome	 of	 the	 transplanted	 cells.	We	 believe	 that	 fur-
ther	 studies	 should	 investigate	 the	 role	 of	 the	 ROCK	 pathway	 in	
HSCR	as	well	as	other	extracellular	 factors	that	play	a	role	 in	ENS	
development. Our work emphasized the importance of the micro-
environment	and	surrounding	cells	for	optimal	ENCC	engraftment,	
proliferation,	migration,	and	differentiation,	which	is	extremely	use-
ful	 for	 improving	 cell-based	 therapeutic	 strategies	 for	 HCSR	 and	
other	ENS-related	disorders.
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